Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

Drug development in oncology is shifting from targeting intrinsic properties of cancer cells to the tumor microenvironmental and the immune system of the host. Boosting T-cell memory may lead to more durable anticancer responses than seen with conventional anticancer therapy [1]. Endogenous anticancer response can be enhanced by blocking inhibitory checkpoint molecules.